The FDA approval of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, for fourth-line therapy of germline BRCA 1/2 mutated ovarian cancer represents the first registered indication for this class of drugs in any disease. PARP is a family of proteins involved in the repair of single-strand DNA breaks. High-grade serous ovarian carcinomas with BRCA deficiencies may be particularly vulnerable to both direct and indirect effects of PARP inhibition. This phenotype frequently arises as a consequence of defects in the repair of damaged DNA, rendering cancer cells susceptible to DNA-damaging platinum compounds and targeted therapies impacting homologous recombination repair (HRR). When cells already deficient in HRR are exposed to PARP inhibitors, apoptosis occurs by way of synthetic lethality. In this review, we trace the clinical development of olaparib for women with recurrent epithelial ovarian carcinoma harboring germline BRCA mutations, a biomarker for HRR deficiency present in 15-20% of cases. Clinical trials highlighted include not only those pivotal studies which have led to regulatory approval in the United States and in Europe, but also those in which olaparib was studied in novel combinations, including chemotherapy and anti-angiogenesis agents.
Pharmacology, Toxicology and Pharmaceutical Science
5
6%
Agricultural and Biological Sciences
4
4%
Economics, Econometrics and Finance
2
2%
Other
10
11%
Unknown
36
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2015.
All research outputs
#16,382,774
of 27,854,867 outputs
Outputs from Clinical Cancer Research
#10,595
of 13,979 outputs
Outputs of similar age
#135,816
of 279,563 outputs
Outputs of similar age from Clinical Cancer Research
#103
of 164 outputs
Altmetric has tracked 27,854,867 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,979 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,563 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 164 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
